Close Menu
  • Home
  • Curly Hair
  • Hair Care
  • Hair Glow
  • Hair Loss
  • Hair Oil
  • Best Hair Care
  • Hair Style
    • Hair Treatment

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

Kyle Richards’ daughter Sofia shows “dramatic” hair loss after taking Munjaro.

May 2, 2025

Best Curly Hair Products of 2024 | Beauty Awards

November 12, 2024

‘I don’t have the courage’: Mira Kapoor expresses fear that her hair won’t grow back if she cuts it Lifestyle News

October 31, 2024
Facebook X (Twitter) Instagram
The Glow Hair
  • Home
  • About Us
  • Advertise with Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
  • Home
  • Curly Hair
  • Hair Care
  • Hair Glow
  • Hair Loss
  • Hair Oil
  • Best Hair Care
  • Hair Style
    • Hair Treatment
The Glow Hair
Home » A peek into the first clinical data begins to reveal the roots of hair removal startup Pelage
Hair Loss

A peek into the first clinical data begins to reveal the roots of hair removal startup Pelage

TheGlowH_AdminBy TheGlowH_AdminFebruary 28, 2024No Comments5 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link


Hair removal is not an underserved market, but it is also not an underserved market. According to Christina Wen, a practicing dermatologist and chief medical officer of Pelage Pharmaceuticals, the available drugs are older products originally developed for other indications and do not address the underlying cause of hair loss. It is said that it has not been addressed.

Based in Los Angeles, Pelage uses a regenerative medicine approach to address hair pathways that are blocked for a variety of reasons and restore hair growth. In its first human trials, the startup found results showing that hair follicle stem cells were activated after seven days of topical application of the experimental drug.

Data from the phase 1 trial has been accepted for presentation at the American Academy of Dermatology meeting in March in San Diego. The company will also begin preparations for a larger Phase 2 clinical trial later this year to evaluate treatments for other types of hair loss, including androgenetic alopecia (pattern baldness) and chemotherapy-induced hair loss. It is planned.

“What we can do is directly approach the stem cells that are the cause (of hair loss),” Wen said. “This is a very clear pathway and is well understood from years of research in the lab.”

Pelage’s technology is based on stem cell research at UCLA. The startup’s scientific co-founders were researching signal transduction that could activate stem cells. That research began to focus on dormant hair follicles. Follicles can become dormant due to age, environment, hormonal changes, stress, medication, and other factors. In these cases, the hair follicles are still present, Wen said, but they just aren’t circulating as well as they used to.

Hair growth occurs in a continuous natural cycle. In addition to the growth phase, there are catagen, resting, and molting phases. Signals from stem cells allow follicles to move from one stage to the next, Wen said. At the end of the resting phase, called the telogen phase, the hair falls out. Professor Wen said hair loss occurs when hair follicles become stuck in the telogen phase and are unable to progress to the anagen phase. Pelage’s drug candidate, codenamed PP405, is a small molecule designed to inhibit the mitochondrial pyruvate carrier (MPC), a protein that plays a role in a variety of physiological processes.

Pelage CEO Daniel Gil said that for hair, blocking MPC is like turning on the metabolism, which has the effect of turning the growth cycle back on. A mouse study conducted by UCLA found that inhibiting MPC accelerates the hair cycle, resulting in normal hair follicle formation within 30 to 40 days after treatment. The results were published in Nature Cell Biology in 2017.

The Phase 1 trial, conducted last fall, enrolled 20 participants, all of whom were men. The primary objective was to evaluate the safety of PP405. Both once and twice daily applications were tested. Minoxidil, a vasodilator that won additional approval for androgenetic alopecia in 1988 and was introduced to the market as “Rogaine,” is applied twice daily.

Pelage’s drug was well tolerated, with no side effects reported in the Phase 1 trial. Gill said Michael Jung, a professor of chemistry and biochemistry at UCLA and one of Pelage’s scientific co-founders, designed PP405 to have the property of keeping the molecule in the scalp and not entering the bloodstream. It is said that he did. Trial results showed that the drug was successful on both counts. The results also show that the molecule engaged the target and provide mechanistic evidence, Wen said.

The Phase 2 clinical trial is expected to enroll approximately 60 participants, both male and female. Wen said it is important to develop drugs that work for all skin types, hair types and genders. Finasteride, first approved in 1992 to treat symptoms of enlarged prostates and later approved for alopecia (sold under names such as Propecia, among others), is known for its ability to increase testosterone levels. Yes, Wen said, but it cannot be used by women. Phase 1 trials showed that once-daily use of PP405 was as effective as twice-daily application, Gill said. Gill also previously oversaw research and early clinical development at beauty giant Allergan. Phase 2 trials will evaluate once-daily dosing of the drug.

In addition to older treatments like minoxidil and finasteride that have received additional approval for hair loss, other treatments are entering the hair loss market, including some that have not been reviewed by the FDA. I am. Injection of stem cells into the scalp is one such unapproved treatment. Gill said the great thing about PP405 is that it works on a patient’s own stem cells.

“You don’t need to inject stem cells into the hair follicle; the stem cells are there,” he says. “This is a great regenerative medicine story.”

Besides Jung, Pelage’s other scientific co-founders are UCLA professors William Rowley and Heather Kristofuk. Pelage was spun out from the university in 2018. The following year, an agreement was reached that gave Allergan an option to acquire the startup. Gill said the deal provided Perage with non-dilutive financial support. Allergan itself was acquired by AbbVie in 2020. After that deal closed, Perage and AbbVie agreed to terminate the option.

Perage plans to use the remainder of its $16.75 million Series A funding, which closed in mid-2023 but was not announced until this week, to fund the Phase 2 trial. Unlike cancer and gene therapy clinical trials, which are expensive and lengthy, hair loss clinical trials are much cheaper because they are quick to enroll and run. Gill said the funding is sufficient to cover both Phase 1 and Phase 2 testing. GV led the Series A round, which included participation from Main Street Advisors, Visionary Ventures, and YK BioVentures.

Photo: Ozanuisaru, Getty Images



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleStudent launches hair care line at Target stores nationwide – @theU
Next Article 11 best brushes for curly hair on Amazon
TheGlowH_Admin
  • Website

Related Posts

Hair Loss

Kyle Richards’ daughter Sofia shows “dramatic” hair loss after taking Munjaro.

By TheGlowH_AdminMay 2, 2025
Hair Loss

Alopecia market growing with progress

By TheGlowH_AdminOctober 31, 2024
Hair Loss

Hair Loss Treatment Market Industry Growth, Demand, and Trends

By TheGlowH_AdminOctober 30, 2024
Hair Loss

Does Creatine Cause Hair Loss? Misconceptions vs. Evidence

By TheGlowH_AdminOctober 30, 2024
Hair Loss

AesMed Co., Ltd., a leading Korean medical hair loss treatment company, participates in Cosmoprof Asia Hong Kong 2024

By TheGlowH_AdminOctober 30, 2024
Hair Loss

AesMed Co., Ltd., a leading Korean medical hair loss treatment company, participates in Cosmoprof Asia Hong Kong 2024

By TheGlowH_AdminOctober 30, 2024
Add A Comment
Leave A Reply Cancel Reply

Don't Miss

Kyle Richards’ daughter Sofia shows “dramatic” hair loss after taking Munjaro.

By TheGlowH_AdminMay 2, 2025

Kyle Richards’ daughter Sofia shows “dramatic” hair loss after taking Mounjaro NBC10. Philadelphia Kill Richards’…

Best Curly Hair Products of 2024 | Beauty Awards

November 12, 2024

‘I don’t have the courage’: Mira Kapoor expresses fear that her hair won’t grow back if she cuts it Lifestyle News

October 31, 2024

Skin and hair care hacks to survive post-festival damage

October 31, 2024
Top Posts

What African women need to know about hair health

October 1, 2024

Keratin hair straightening treatment caused kidney damage in this 26-year-old woman. Experts reveal what happened

October 1, 2024

How hirsutism affects the time, wallet, and well-being of many women with PCOS

October 1, 2024

Doctors say adding £1 item to shampoo ‘helps hair growth’

September 30, 2024

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

About Us
About Us

Welcome to The Glow Hair, your ultimate destination for all things hair! Our mission is to keep you informed and inspired with the latest trends, news, and tips in the world of hair care and styling.

Facebook X (Twitter) Pinterest YouTube WhatsApp
Our Picks

Kyle Richards’ daughter Sofia shows “dramatic” hair loss after taking Munjaro.

May 2, 2025

Best Curly Hair Products of 2024 | Beauty Awards

November 12, 2024

‘I don’t have the courage’: Mira Kapoor expresses fear that her hair won’t grow back if she cuts it Lifestyle News

October 31, 2024
Most Popular

Kyle Richards’ daughter Sofia shows “dramatic” hair loss after taking Munjaro.

May 2, 2025

US Soldier Dead After A Truck Hit His Military Vehicle On A Highway

January 5, 2020

The Masked Singer 2024: Chicken Caesar Becomes Second Celebrity Contestant Revealed

January 6, 2020
  • Home
  • About Us
  • Advertise with Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2025 theglowhair. Designed by theglowhair.

Type above and press Enter to search. Press Esc to cancel.